CheckMate-227: Bristol-Myers Squibb has a MYSTIC-sized problem on its hands
Nobody knows how to put a top exec on the spot quite like Goldman Sach’s Jami Rubin.
The high-profile analyst has a well-earned rep for going straight for the jugular, and that was on full display Thursday night as she went at Bristol-Myers Squibb’s latest potential Achilles heel in immuno-oncology: Its CheckMate 227 trial that includes a matchup of Opdivo and the CTLA-4 drug Yervoy in front-line lung cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.